Featured Research

from universities, journals, and other organizations

Breakthrough in RSV research with drug trial

Date:
August 28, 2014
Source:
Le Bonheur Children's Hospital
Summary:
A new clinical trial of a drug was shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV). RSV is the most common cause of lower respiratory tract infections in young children in the United States and worldwide. It hospitalizes 125,000 children in the United States each year, and was the cause for 1.5 million outpatient visits.

The New England Journal of Medicine published research results on Aug. 21 from a clinical trial of a drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV).

Related Articles


Le Bonheur Children's Hospital and the University of Tennessee Health Science Center researcher Infectious Disease Specialist John DeVincenzo, MD, is lead author of this study.

RSV is the most common cause of lower respiratory tract infections in young children in the United States and worldwide. It hospitalizes 125,000 children in the United States each year, and was the cause for 1.5 million outpatient visits, according to the Centers for Disease Control and Prevention (CDC). DeVincenzo and his fellow researchers have been part of virtually every experimental therapeautic advancement, developmental pathway and antiviral therapy created to tackle the virus in the past 15 years.

"No effective antiviral treatment currently exists for RSV, which is the leading cause of severe childhood respiratory infections, and is extremely dangerous for babies and children," said DeVincenzo. "We were pleased that our study, for the first time, shows that the infection caused by the RSV virus can be effectively reduced after the infection has started. This is also the first time to prove that once we reduce the amount of virus in a patient, they begin to feel better very quickly. The next step is to explore clinical trials in naturally infected patients."

The challenge study of Gilead Sciences Inc.'s GS-5806, an investigational oral RSV fusion inhibitor, achieved primary and secondary endpoints of lower viral load, improvements in total mucus weight and symptom diary score compared to placebo. Volunteers in the study were given the oral drug after being infected with RSV using the experimental challenge model. The model is based on a clinical isolate from an infant hospitalized with RSV bronchiolitis which can be safely used to infect adults, and that was developed by DeVincenzo in 2007 to test proof-of-concept antivirals.


Story Source:

The above story is based on materials provided by Le Bonheur Children's Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. John P. DeVincenzo, Richard J. Whitley, Richard L. Mackman, Cecilia Scaglioni-Weinlich, Lisa Harrison, Eric Farrell, Stephen McBride, Robert Lambkin-Williams, Robert Jordan, Yan Xin, Srini Ramanathan, Thomas O’Riordan, Sandra A. Lewis, Xiaoming Li, Seth L. Toback, Shao-Lee Lin, Jason W. Chien. Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study. New England Journal of Medicine, 2014; 371 (8): 711 DOI: 10.1056/NEJMoa1401184

Cite This Page:

Le Bonheur Children's Hospital. "Breakthrough in RSV research with drug trial." ScienceDaily. ScienceDaily, 28 August 2014. <www.sciencedaily.com/releases/2014/08/140828170015.htm>.
Le Bonheur Children's Hospital. (2014, August 28). Breakthrough in RSV research with drug trial. ScienceDaily. Retrieved October 26, 2014 from www.sciencedaily.com/releases/2014/08/140828170015.htm
Le Bonheur Children's Hospital. "Breakthrough in RSV research with drug trial." ScienceDaily. www.sciencedaily.com/releases/2014/08/140828170015.htm (accessed October 26, 2014).

Share This



More Health & Medicine News

Sunday, October 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
Toxin-Packed Stem Cells Used To Kill Cancer

Toxin-Packed Stem Cells Used To Kill Cancer

Newsy (Oct. 25, 2014) — A Harvard University Research Team created genetically engineered stem cells that are able to kill cancer cells, while leaving other cells unharmed. Video provided by Newsy
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins